secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2024-08-28T23:59:59+00:00
Accession:  0001493152-24-034098
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma receives NYSE American trading halt due to low price; plans 1-for-50 reverse split
--------------------------------------------------------------------------------

- Trading of MTNB common stock halted by NYSE American on August 27, 2024 due to low trading price.
- Halt to remain until reverse stock split (1-for-50) is consummated; split effective 5:00 PM EST on August 30, 2024.
- Split-adjusted trading expected to begin September 3, 2024, subject to NYSE American approval.
- If post-split price does not meet Section 1003(f)(v) requirements, NYSE could suspend trading and delist shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224034098/0001493152-24-034098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224034098/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-034098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer